focus -WSS

focus

author：comprehensive 2025-09-29 12:09:04 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Histogen: Failed biotech offers rare public look inside

entertainment

focus

WSS

A controversial new treatment promises to make little people taller

Chemotherapy drug shortage eases slightly but still widespread

The a glaring gap in research on serious mental illness and primary care

How I helped Pfizer think through the ethics of Viagra

Personalized medicine goes far beyond genetics

When women are denied an abortion, their children fare worse than peers

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Physician executives need more than on

BioMarin wins approval for gene therapy to treat hemophilia A

Group behind ProMed defends move to subscription

Peter Hotez and the public health issue of online harassment

Medicare slashes safety net hospital payments by nearly $1 billion

Supreme Court strikes down use of affirmative action

Bill would stop addiction treatment from triggering child abuse inquiry

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Group behind ProMed defends move to subscription

hotspot

When waiting feels immoral: Empathy in the emergency department

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

FDA panel signals lack of confidence in Amgen cancer drug data

Study links childhood stress with decline in older age

Biotech startup Celsius cuts 75% of staff ahead of first trial start

leisure time

entertainment

focus

hotspot